PE20191080A1 - Anticuerpo biespecifico heterodimerico estructural de anticuerpo natural anti-pd-1/anti-her2 y metodo para preparar el mismo - Google Patents
Anticuerpo biespecifico heterodimerico estructural de anticuerpo natural anti-pd-1/anti-her2 y metodo para preparar el mismoInfo
- Publication number
- PE20191080A1 PE20191080A1 PE2019001036A PE2019001036A PE20191080A1 PE 20191080 A1 PE20191080 A1 PE 20191080A1 PE 2019001036 A PE2019001036 A PE 2019001036A PE 2019001036 A PE2019001036 A PE 2019001036A PE 20191080 A1 PE20191080 A1 PE 20191080A1
- Authority
- PE
- Peru
- Prior art keywords
- antibody
- chain
- her2
- prepare
- binding
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
Se refiere a un anticuerpo biespecifico heterodimerico que comprende un primer dominio funcional de union a antigeno capaz de unirse especificamente a PD-1 y un segundo dominio funcional de union a antigeno capaz de unirse especificamente a HER2, comprendiendo el anticuerpo una primera cadena Fc y una segunda cadena Fc unidas entre si por uno o mas enlaces disulfuro, y unidas a los dominios funcionales de union a antigeno PD-1 y HER2 mediante enlace covalente o enlazador, comprendiendo estas cadenas 5 sustituciones de aminoacidos: en las posiciones T366 y D399 (o K409) de la primera cadena Fc y en las posiciones L351, Y407 y K409 (o D399) de la segunda cadena Fc, tendiendo las cadenas a experimentar heterodimerizacion. Tambien se refiere a un polinucleotido aislado que codifica al anticuerpo, un vector de expresion y una celula huesped que comprenden al polinucleotido, una composicion que comprende el anticuerpo, y metodos de preparacion. La presente invencion es util para el tratamiento de enfermedades complejas tales como leucemia, linfoma, entre otras
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611016435 | 2016-11-18 | ||
| PCT/CN2017/111310 WO2018090950A1 (zh) | 2016-11-18 | 2017-11-16 | 抗pd‐1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20191080A1 true PE20191080A1 (es) | 2019-08-20 |
Family
ID=62146170
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019001036A PE20191080A1 (es) | 2016-11-18 | 2017-11-16 | Anticuerpo biespecifico heterodimerico estructural de anticuerpo natural anti-pd-1/anti-her2 y metodo para preparar el mismo |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US11319378B2 (es) |
| EP (1) | EP3533804A4 (es) |
| JP (1) | JP7031810B2 (es) |
| KR (1) | KR102247704B1 (es) |
| CN (1) | CN109963876B (es) |
| AU (1) | AU2017359813A1 (es) |
| BR (1) | BR112019010051A2 (es) |
| CA (1) | CA3043652A1 (es) |
| CL (1) | CL2019001352A1 (es) |
| CO (1) | CO2019005101A2 (es) |
| DO (1) | DOP2019000124A (es) |
| EA (1) | EA201990894A9 (es) |
| EC (1) | ECSP19035482A (es) |
| MX (1) | MX2019005858A (es) |
| PE (1) | PE20191080A1 (es) |
| PH (1) | PH12019501089A1 (es) |
| SG (1) | SG10201913260VA (es) |
| TN (1) | TN2019000161A1 (es) |
| WO (1) | WO2018090950A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017336867B2 (en) * | 2016-09-29 | 2024-03-14 | Beijing Hanmi Pharmaceutical Co., Ltd. | Heterodimeric immunoglobulin constructs and preparation methods thereof |
| EP3533804A4 (en) | 2016-11-18 | 2020-06-17 | Beijing Hanmi Pharmaceutical Co., Ltd. | BISPECIFIC ANTIBODY TYPE ANTI-PD -1 / ANTI-HER2 NATURAL ANTIBODY HETERODIMERIC FORM AND PREPARATION THEREOF |
| KR20200093639A (ko) * | 2017-12-04 | 2020-08-05 | 북경한미약품 유한공사 | 천연 항체 구조-유사 헤테로다이머 형태의 항 pd-l1/항 cd47 이중특이성 항체 및 이의 제조 |
| WO2019153200A1 (zh) | 2018-02-08 | 2019-08-15 | 北京韩美药品有限公司 | 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备 |
| TWI825214B (zh) * | 2018-11-05 | 2023-12-11 | 中國大陸商北京韓美藥品有限公司 | 抗TNFα/抗IL-17A天然抗體結構樣異源二聚體形式雙特異抗體及其製備 |
| CN111196856A (zh) * | 2018-11-19 | 2020-05-26 | 三生国健药业（上海）股份有限公司 | 抗her2/pd1双特异性抗体 |
| CN111378045B (zh) * | 2018-12-28 | 2022-08-02 | 长春金赛药业有限责任公司 | 二价双特异性抗体及其制备方法、编码基因、宿主细胞、组合物 |
| EP4011390A4 (en) * | 2019-08-07 | 2023-09-13 | Innovent Biologics (Suzhou) Co., Ltd. | PREPARATION WITH ANTI-PD-1/HER2 BISPECIFIC ANTIBODY AND METHOD FOR THE PRODUCTION AND USE THEREOF |
| CN111995685B (zh) * | 2020-04-30 | 2022-03-08 | 中国科学院上海药物研究所 | 一种靶向her2和pd-1的双特异性抗体及其应用 |
| WO2024061223A1 (zh) * | 2022-09-20 | 2024-03-28 | 普米斯生物技术(珠海)有限公司 | 抗体及其在抗肿瘤中的应用 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL9100352A (nl) | 1991-02-27 | 1992-09-16 | Hoogovens Groep Bv | Werkwijze voor het vervaardigen van ijzerfolie door elektrodepositie. |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5869046A (en) * | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| ATE321066T1 (de) * | 1998-05-06 | 2006-04-15 | Genentech Inc | Anti-her2 antikörperzusammensetzung |
| US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| US20060074225A1 (en) | 2004-09-14 | 2006-04-06 | Xencor, Inc. | Monomeric immunoglobulin Fc domains |
| DK2170959T3 (da) | 2007-06-18 | 2014-01-13 | Merck Sharp & Dohme | Antistoffer mod human programmeret dødsreceptor pd-1 |
| PT2235064E (pt) | 2008-01-07 | 2016-03-01 | Amgen Inc | Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática |
| CA2759333A1 (en) | 2009-04-22 | 2010-10-28 | Merck Patent Gmbh | Antibody fusion proteins with modified fcrn binding sites |
| JP2013511281A (ja) | 2009-11-23 | 2013-04-04 | アムジェン インコーポレイテッド | 単量体抗体Ｆｃ |
| AU2011325833C1 (en) | 2010-11-05 | 2017-07-13 | Zymeworks Bc Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| EA028804B1 (ru) | 2011-03-25 | 2018-01-31 | Гленмарк Фармасьютикалс С.А. | Гетеродимерные иммуноглобулины |
| LT2699264T (lt) | 2011-04-20 | 2018-07-10 | Medimmune, Llc | Antikūnai ir kitos molekulės, kurios jungiasi prie b7-h1 ir pd-1 |
| CN104114579B (zh) | 2011-10-27 | 2020-01-24 | 健玛保 | 异二聚体蛋白的生成 |
| WO2013063702A1 (en) | 2011-11-04 | 2013-05-10 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the fc domain |
| MX360109B (es) | 2012-04-20 | 2018-10-23 | Merus Nv | Metodos y medios para la produccion de moleculas de tipo ig. |
| AU2013322710A1 (en) | 2012-09-25 | 2015-04-16 | Glenmark Pharmaceuticals S.A. | Purification of hetero-dimeric immunoglobulins |
| CA2889951C (en) | 2012-11-02 | 2023-04-18 | Zymeworks Inc. | Crystal structures of heterodimeric fc domains |
| US9914785B2 (en) | 2012-11-28 | 2018-03-13 | Zymeworks Inc. | Engineered immunoglobulin heavy chain-light chain pairs and uses thereof |
| WO2014082179A1 (en) | 2012-11-28 | 2014-06-05 | Zymeworks Inc. | Engineered immunoglobulin heavy chain-light chain pairs and uses thereof |
| JP6392770B2 (ja) | 2012-12-03 | 2018-09-19 | ノビミューン エスアー | 抗ｃｄ４７抗体およびその使用方法 |
| JP6586087B2 (ja) * | 2013-08-20 | 2019-10-02 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | Ｐｄ−１アンタゴニストとジナシクリブとの組合せでの癌治療 |
| EP3083692B1 (en) | 2013-12-17 | 2020-02-19 | F.Hoffmann-La Roche Ag | Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies |
| WO2015095412A1 (en) * | 2013-12-19 | 2015-06-25 | Zhong Wang | Bispecific antibody with two single-domain antigen-binding fragments |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| WO2016024021A1 (en) | 2014-08-15 | 2016-02-18 | Merck Patent Gmbh | Sirp-alpha immunoglobulin fusion proteins |
| CN107428825A (zh) | 2014-10-10 | 2017-12-01 | 创祐生技股份有限公司 | 治疗及/或预防肿瘤生长、侵袭及/或转移的方法 |
| WO2016109415A1 (en) | 2014-12-30 | 2016-07-07 | Celgene Corporation | Anti-cd47 antibodies and uses thereof |
| EP3245227A4 (en) | 2015-01-14 | 2018-07-25 | Compass Therapeutics LLC | Multispecific immunomodulatory antigen-binding constructs |
| WO2016170039A1 (en) | 2015-04-23 | 2016-10-27 | F. Hoffmann-La Roche Ag | Combination therapy of antibody binding to angiopoietin 2 with antibody binding to programmed death 1 polypeptide |
| TW201709929A (zh) * | 2015-06-12 | 2017-03-16 | 宏觀基因股份有限公司 | 治療癌症的聯合療法 |
| CN105111314B (zh) | 2015-08-13 | 2019-01-08 | 成都百世博生物技术有限公司 | 一种新型融合蛋白、药物组合物及其制备方法和用途 |
| CN105175545B (zh) | 2015-10-20 | 2019-01-25 | 安徽瀚海博兴生物技术有限公司 | 一种抗vegf-抗pd-1双功能抗体及其应用 |
| CN106883297B (zh) | 2015-12-16 | 2019-12-13 | 苏州康宁杰瑞生物科技有限公司 | 基于ch3结构域的异二聚体分子、其制备方法及用途 |
| WO2017117179A1 (en) | 2015-12-28 | 2017-07-06 | Massachusetts Institute Of Technology | Bispecific antibodies having constant region mutations and uses therefor |
| WO2017167350A1 (en) | 2016-03-30 | 2017-10-05 | Horst Lindhofer | Multispecific antibodies for use in the treatment of a neoplasm of the urinary tract |
| GB201611530D0 (en) | 2016-07-01 | 2016-08-17 | Alligator Bioscience Ab | Novel polypeptides |
| AU2017336867B2 (en) | 2016-09-29 | 2024-03-14 | Beijing Hanmi Pharmaceutical Co., Ltd. | Heterodimeric immunoglobulin constructs and preparation methods thereof |
| KR20190065183A (ko) | 2016-10-15 | 2019-06-11 | 이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 | Pd-1 항체 |
| EP3533804A4 (en) | 2016-11-18 | 2020-06-17 | Beijing Hanmi Pharmaceutical Co., Ltd. | BISPECIFIC ANTIBODY TYPE ANTI-PD -1 / ANTI-HER2 NATURAL ANTIBODY HETERODIMERIC FORM AND PREPARATION THEREOF |
| AU2018243104A1 (en) | 2017-04-01 | 2019-10-17 | Beijing Hanmi Pharm. Co., Ltd. | Anti-PD-L1/anti-PD-1 natural antibody structure-like heterodimeric bispecific antibody and preparation thereof |
| AR112603A1 (es) | 2017-07-10 | 2019-11-20 | Lilly Co Eli | Anticuerpos biespecíficos inhibidores de punto de control |
| CN107325184A (zh) | 2017-08-08 | 2017-11-07 | 安徽大学 | 一种靶向egfr和her2的双特异性抗体及其应用 |
| EA039662B1 (ru) | 2017-10-03 | 2022-02-24 | Закрытое Акционерное Общество "Биокад" | Антитела, специфичные к cd47 и pd-l1 |
| KR20200093639A (ko) | 2017-12-04 | 2020-08-05 | 북경한미약품 유한공사 | 천연 항체 구조-유사 헤테로다이머 형태의 항 pd-l1/항 cd47 이중특이성 항체 및 이의 제조 |
| WO2019153200A1 (zh) | 2018-02-08 | 2019-08-15 | 北京韩美药品有限公司 | 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备 |
| CA3090878A1 (en) | 2018-02-11 | 2019-08-15 | Beijing Hanmi Pharmaceutical Co., Ltd. | Anti-pd-1/anti-vegf natural antibody structure-like heterodimeric form bispecific antibody and preparation thereof |
-
2017
- 2017-11-16 EP EP17871719.5A patent/EP3533804A4/en active Pending
- 2017-11-16 US US16/461,646 patent/US11319378B2/en active Active
- 2017-11-16 JP JP2019527168A patent/JP7031810B2/ja active Active
- 2017-11-16 CN CN201780071590.9A patent/CN109963876B/zh active Active
- 2017-11-16 TN TNP/2019/000161A patent/TN2019000161A1/en unknown
- 2017-11-16 KR KR1020197013134A patent/KR102247704B1/ko active IP Right Grant
- 2017-11-16 WO PCT/CN2017/111310 patent/WO2018090950A1/zh unknown
- 2017-11-16 CA CA3043652A patent/CA3043652A1/en active Pending
- 2017-11-16 SG SG10201913260VA patent/SG10201913260VA/en unknown
- 2017-11-16 MX MX2019005858A patent/MX2019005858A/es unknown
- 2017-11-16 PE PE2019001036A patent/PE20191080A1/es unknown
- 2017-11-16 EA EA201990894A patent/EA201990894A9/ru unknown
- 2017-11-16 AU AU2017359813A patent/AU2017359813A1/en active Pending
- 2017-11-16 BR BR112019010051A patent/BR112019010051A2/pt active Search and Examination
-
2019
- 2019-05-16 PH PH12019501089A patent/PH12019501089A1/en unknown
- 2019-05-17 DO DO2019000124A patent/DOP2019000124A/es unknown
- 2019-05-17 CO CONC2019/0005101A patent/CO2019005101A2/es unknown
- 2019-05-17 CL CL2019001352A patent/CL2019001352A1/es unknown
- 2019-05-17 EC ECSENADI201935482A patent/ECSP19035482A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018090950A1 (zh) | 2018-05-24 |
| EA201990894A1 (ru) | 2019-09-30 |
| US11319378B2 (en) | 2022-05-03 |
| KR102247704B1 (ko) | 2021-05-03 |
| US20190367633A1 (en) | 2019-12-05 |
| EP3533804A1 (en) | 2019-09-04 |
| SG10201913260VA (en) | 2020-03-30 |
| EA201990894A9 (ru) | 2019-11-27 |
| ECSP19035482A (es) | 2019-05-31 |
| CO2019005101A2 (es) | 2019-05-31 |
| DOP2019000124A (es) | 2019-11-15 |
| TN2019000161A1 (en) | 2020-10-05 |
| BR112019010051A2 (pt) | 2019-09-03 |
| EP3533804A4 (en) | 2020-06-17 |
| JP7031810B2 (ja) | 2022-03-08 |
| CN109963876B (zh) | 2023-11-14 |
| CL2019001352A1 (es) | 2019-08-02 |
| PH12019501089A1 (en) | 2020-03-02 |
| AU2017359813A1 (en) | 2019-05-30 |
| JP2020510407A (ja) | 2020-04-09 |
| KR20190065375A (ko) | 2019-06-11 |
| MX2019005858A (es) | 2019-08-12 |
| CA3043652A1 (en) | 2018-05-24 |
| CN109963876A (zh) | 2019-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20191080A1 (es) | Anticuerpo biespecifico heterodimerico estructural de anticuerpo natural anti-pd-1/anti-her2 y metodo para preparar el mismo | |
| PE20191034A1 (es) | Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15r y fragmentos de anticuerpo pd-1 | |
| PE20211418A1 (es) | Receptores quimericos y metodos de uso de los mismos | |
| PE20240218A1 (es) | Anticuerpos madurados por afinidad y humanizados para fcrh5 | |
| PE20211696A1 (es) | Moleculas agonistas de union al antigeno cd28 que actuan sobre el tumor | |
| PE20181451A1 (es) | Anticuerpos neutralizadores del virus de inmunodeficiencia humana | |
| CO2019003923A2 (es) | Anticuerpos anti-steap2, conjugados anticuerpo-fármaco, y moléculas de fijación al antígeno biespecíficas que se fijan a steap2 y cd3, y usos de estos | |
| PE20181018A1 (es) | Anticuerpos anti-pd-1 novedosos | |
| PH12019502561A1 (en) | Novel monoclonal antibodies to cytotoxic t-lymphocyte-associated protein 4 (ctla-4) | |
| AU2018258045A1 (en) | Chimeric antibody/T-cell receptor constructs and uses thereof | |
| AR087615A1 (es) | Moleculas biespecificas de union a antigeno | |
| PE20220495A1 (es) | Receptores antigenicos quimericos y agentes de union dirigidos a dll3 | |
| CO2018002360A2 (es) | Anticuerpos biespecíficos contra el a-beta humano y el receptor de transferrina humano y métodos de uso | |
| JOP20180042A1 (ar) | نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام | |
| AR110676A1 (es) | Tratamiento del cáncer utilizando receptores de antígenos quiméricos | |
| CR20180484A (es) | Moléculas de unón b7-h3 novedosas, conjugados anticuerpos-fármaco de los mismos y métodos de uso de los mismos | |
| PE20210180A1 (es) | Anticuerpos anti-cd33, anticuerpos biespecificos anti-cd33/anti-cd3 y usos de estos | |
| PE20231958A1 (es) | Moleculas de union a pd-1 y metodos de uso de las mismas | |
| PE20200384A1 (es) | Metodo de fabricacion de anticuerpos bispecificos, anticuerpos bispecificos y uso terapeutico de dichos anticuerpos | |
| AR096617A1 (es) | Anticuerpos anti-tweakr y sus usos | |
| PE20211284A1 (es) | Anticuerpos anti-nkg2a y usos de los mismos | |
| DOP2014000007A (es) | Proteinas de union a antigeno de tnf-alfa con union a fcrn incrementada | |
| EA201990285A1 (ru) | Гетеродимерные иммуноглобулиновые конструкции и способы их получения | |
| EA201590208A1 (ru) | Усиление активности т-клеток car путем совместного введения биспецифического антитела | |
| PE20191759A1 (es) | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos |